Skip to main content
SIR 2026 Event Main banner

SIR 2026

Scientific Session

Arterial Interventions

Session: Arterial Interventions

8 - Endovascular Management of Peripheral Arterial Hemorrhage Using the Low-Profile Braided Occluder (LOBO®): A Single-Center Experience

Sunday, April 12, 2026
3:45 PM - 3:54 PM ET
Purpose: To evaluate the technical feasibility, safety, and clinical efficacy of the Low-profile Braided Occluder (LOBO) (Okami Medical, Aliso Viejo, California) device in the management of acute peripheral arterial hemorrhage at a single-center.

Materials and Methods: This retrospective single-center study included consecutive patients who underwent embolization for peripheral arterial hemorrhage with the LOBO device between June 2023 and May 2025. Patient demographics, etiology of the bleed, target vessel location, device size, number of devices used, technical success, clinical success, and adverse events were analyzed. Technical success was defined as complete angiographic occlusion of the target vessel. Clinical success was defined as cessation of hemorrhage without the need for reintervention or surgery within 30 days of embolization.

Results: Overall, 36 patients (mean age, 60.75 ± 19.2 years; 21 females, 15 males) with a total of 66 embolized vessels were included. Iatrogenic bleeding was the most common etiology, 19 (52.8%), followed by trauma, 8 (22.2%), and gastrointestinal ulcers, 3 (8.3%). The most frequently embolized territory was the gastroduodenal–pancreaticoduodenal arcade, 17 (28.3%).

A total of 69 LOBO devices were deployed: LOBO-3, 46 (66.7%); LOBO-5, 17 (24.6%); LOBO-7, 5 (7.3%); and LOBO-9, 1 (1.5%). All target vessels were successfully occluded, resulting in 100% technical success. Three arteries required more than one device, except in pancreaticoduodenal arcade embolization, where two devices are routinely used.

Clinical success was observed in 32 (88.9%) of 36 patients. All four patients with failed clinical success underwent repeat embolization, with rebleeding from a second artery—different from the initially embolized vessel—classified as a grade 3 adverse event according to SIR classification {1}. Additionally, there were no device-related adverse events.

Conclusion: The LOBO device demonstrated high technical and clinical efficacy with a favorable safety profile for embolization of arterial hemorrhage across a wide variety of vascular territories. Larger multi-center studies are warranted to further evaluate the role of the device in acute hemorrhage management.